Occident Group AG

Occident Group AG

Siegbert Schützenhöfer established the original life-insurance brokerage in 1993. Patrizia Schützenhöfer and Michael Pauer shifted the family’s deployment into venture capital in 2012, focusing on spin-offs from scientific research. The office maintains its legal base in Zug while operating the investment team from Munich. The firm deploys proprietary capital through direct co-investments and SPVs into growth-stage companies. Asset classes include venture equity, private equity secondaries, real estate and special situations. Confirmed holdings include Lymphatica Medtech, ReCatalyst, core sensing, InSphero and G-Metrics. Additional positions appear in Tubulis, adivo and Lunaphore prior to their exits. Activity spans Switzerland, Germany, Austria, Slovenia, Finland and Canada. Occident Group AG reports more than 25 active portfolio companies and at least five exits. The team includes Cédric Barra and Paul Sunzenauer in life sciences. A second office opened in Munich in 2019 and became the investment headquarters in 2021. Spring 2026: Portfolio company Tubulis was acquired by Gilead Sciences for $3.15 billion plus up to $1.85 billion in milestones. The office belongs to SECA and the Swiss Biotech Association. Ownership remains with the Schützenhöfer family. Patrizia Schützenhöfer holds final authority on all investment decisions and maintains separation between the venture book and the legacy real-estate and insurance assets. This structure allows the office to operate without external limited partners while preserving long-term holding periods across both venture and property portfolios.